Literature DB >> 17627238

Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation.

Speranta Iacob1, Vito R Cicinnati, Philip Hilgard, Razvan A Iacob, Liana S Gheorghe, Irinel Popescu, Andrea Frilling, Massimo Malago, Guido Gerken, Christoph E Broelsch, Susanne Beckebaum.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) recurrence after liver transplantation (LT) is almost universal, but the natural history of recurrent HCV in the allograft is highly variable. Our study had two aims: 1) to assess the impact of different pre- and postLT factors on graft and patient survival in HCV transplant recipients and 2) to create a model which may predict the patients at risk for HCV-related graft cirrhosis at 5 years postLT.
METHODS: A total of 168 LTs were considered for this study. Univariate and multivariate Cox proportional hazards regression model was used, as well as logistic regression analysis to create a model of prediction of HCV cirrhosis within 5 years after LT.
RESULTS: Predictive factors for both decreased graft and patient survival included patients recently transplanted (2000-2004), induction without azathioprine, short-term therapy with mycophenolate mofetil and prednisone (< or =6 months), presence of early cholestasis, histologically proven early recurrence of hepatitis C. Recipient human leukocyte antigen DR3 positivity, presence of early cholestasis, and donor age >50 years were identified as independent predictors of graft cirrhosis within 5 years. A predictive model was established in order to calculate at 6 months a risk score for graft HCV cirrhosis within 5 years postLT using a formula that included the identified independent predictors. The area under receiver operating characteristic curve was 0.83, indicating a good ability to predict medium-term HCV allograft cirrhosis.
CONCLUSION: This model may be a useful tool for better identifying high-risk HCV patients who should be selected for early initiation of antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627238     DOI: 10.1097/01.tp.0000267916.36343.ca

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.

Authors:  Brett E Fortune; Alvaro Martinez-Camacho; Sarah Kreidler; Jane Gralla; Gregory T Everson
Journal:  Transpl Int       Date:  2015-04-16       Impact factor: 3.782

Review 2.  Using old liver grafts for liver transplantation: where are the limits?

Authors:  Carlos Jiménez-Romero; Oscar Caso Maestro; Félix Cambra Molero; Iago Justo Alonso; Cristina Alegre Torrado; Alejandro Manrique Municio; Jorge Calvo Pulido; Carmelo Loinaz Segurola; Enrique Moreno González
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Impact of anti-thymocyte globulin during immunosuppression induction in patients with hepatitis C after liver transplantation.

Authors:  Mauricio Garcia-Saenz-de-Sicilia; Marco A Olivera-Martinez; Wendy J Grant; David F Mercer; Chen Baojjang; Alan Langnas; Timothy McCashland
Journal:  Dig Dis Sci       Date:  2014-05-28       Impact factor: 3.199

4.  Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men.

Authors:  Jennifer C Lai; Elizabeth C Verna; Robert S Brown; Jacqueline G O'Leary; James F Trotter; Lisa M Forman; Jeffrey D Duman; Richard G Foster; R Todd Stravitz; Norah A Terrault
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

5.  Long-term results using old liver grafts for transplantation: sexagenerian versus liver donors older than 70 years.

Authors:  Carlos Jiménez-Romero; Marta Clemares-Lama; Alejandro Manrique-Municio; Alvaro García-Sesma; Jorge Calvo-Pulido; Enrique Moreno-González
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

6.  Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.

Authors:  Wei Liu; Bolong Yu; Yunfan Luo; Junzheng Li; Xiaofei Yuan; Shuting Wu; Bijun Liang; Zehong Lv; Yanfei Li; Xinyu Peng; Juan Lu; Xiaohong Peng; Xiong Liu
Journal:  BMC Cancer       Date:  2021-05-29       Impact factor: 4.430

7.  Conversion to combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy for renal dysfunction in liver transplant patients: never too late?

Authors:  Susanne Beckebaum; Vito R Cicinnati
Journal:  Dig Dis Sci       Date:  2011-01       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.